-
1
-
-
24344471811
-
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005
-
Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
-
(2005)
Br J Dermatol
, vol.153
, pp. 486-497
-
-
Smith, C.H.1
Anstey, A.V.2
Barker, J.N.3
-
2
-
-
38549176118
-
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
-
Tracey D, Klareskog L, Sasso EH et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 2008 117 : 244 279.
-
(2008)
Pharmacol Ther
, vol.117
, pp. 244-279
-
-
Tracey, D.1
Klareskog, L.2
Sasso, E.H.3
-
4
-
-
0028233818
-
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions
-
Ettehadi P, Greaves MW, Wallach D et al. Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994 96 : 146 151.
-
(1994)
Clin Exp Immunol
, vol.96
, pp. 146-151
-
-
Ettehadi, P.1
Greaves, M.W.2
Wallach, D.3
-
5
-
-
77952723879
-
TNF blockade: An inflammatory issue
-
Numerof, R. Dinarello, C.A. Asadullah, K. eds)
-
Aggarwal BB, Shishodia S, Takada Y et al. TNF blockade: An inflammatory issue. In : Cytokines as Potential Therapeutic Targets for Inflammatory Skin Diseases. Ernst Schering Research Foundation Workshop (Numerof R, Dinarello CA, Asadullah K, eds).
-
Cytokines As Potential Therapeutic Targets for Inflammatory Skin Diseases. Ernst Schering Research Foundation Workshop
-
-
Aggarwal, B.B.1
Shishodia, S.2
Takada, Y.3
-
6
-
-
0346848881
-
Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis
-
Victor FC, Gottlieb AB, Menter A. Changing paradigms in dermatology: Tumor necrosis factor alpha (TNF-alpha) blockade in psoriasis and psoriatic arthritis. Clin Dermatol 2003 21 : 392 397.
-
(2003)
Clin Dermatol
, vol.21
, pp. 392-397
-
-
Victor, F.C.1
Gottlieb, A.B.2
Menter, A.3
-
7
-
-
35448935612
-
Biological and clinical effects of anti-TNFalpha treatment
-
Valesini G, Iannuccelli C, Marocchi E et al. Biological and clinical effects of anti-TNFalpha treatment. Autoimmun Rev 2007 7 : 35 41.
-
(2007)
Autoimmun Rev
, vol.7
, pp. 35-41
-
-
Valesini, G.1
Iannuccelli, C.2
Marocchi, E.3
-
8
-
-
33748936662
-
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
-
Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006 55 : 598 606.
-
(2006)
J Am Acad Dermatol
, vol.55
, pp. 598-606
-
-
Gordon, K.B.1
Langley, R.G.2
Leonardi, C.3
-
9
-
-
37349003068
-
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
-
Menter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008 58 : 106 115.
-
(2008)
J Am Acad Dermatol
, vol.58
, pp. 106-115
-
-
Menter, A.1
Tyring, S.K.2
Gordon, K.3
-
10
-
-
36849070806
-
Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis
-
Revicki DA, Willian MK, Menter A et al. Impact of adalimumab treatment on patient-reported outcomes: Results from a phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat 2007 18 : 341 350.
-
(2007)
J Dermatolog Treat
, vol.18
, pp. 341-350
-
-
Revicki, D.A.1
Willian, M.K.2
Menter, A.3
-
11
-
-
39049143819
-
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
-
Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008 158 : 558 566.
-
(2008)
Br J Dermatol
, vol.158
, pp. 558-566
-
-
Saurat, J.H.1
Stingl, G.2
Dubertret, L.3
-
12
-
-
34548535119
-
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation
-
Marble DJ, Gordon KB, Nickoloff BJ. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci 2007 48 : 87 101.
-
(2007)
J Dermatol Sci
, vol.48
, pp. 87-101
-
-
Marble, D.J.1
Gordon, K.B.2
Nickoloff, B.J.3
-
13
-
-
27544465904
-
The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques
-
Gordon KB, Bonish BK, Patel T et al. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol 2005 153 : 945 953.
-
(2005)
Br J Dermatol
, vol.153
, pp. 945-953
-
-
Gordon, K.B.1
Bonish, B.K.2
Patel, T.3
-
14
-
-
14044252848
-
Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept
-
Shen C, van Assche G, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: A comparative study with infliximab and etanercept. Aliment Pharmacol Ther 2005 21 : 251 258.
-
(2005)
Aliment Pharmacol Ther
, vol.21
, pp. 251-258
-
-
Shen, C.1
Van Assche, G.2
Colpaert, S.3
-
15
-
-
29744441553
-
Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model
-
Shen C, van Assche G, Rutgeerts P et al. Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model. Inflamm Bowel Dis 2006 12 : 22 8.
-
(2006)
Inflamm Bowel Dis
, vol.12
, pp. 22-8
-
-
Shen, C.1
Van Assche, G.2
Rutgeerts, P.3
-
16
-
-
13244284850
-
The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin
-
Johansen C, Kragballe K, Westergaard M et al. The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br J Dermatol 2005 152 : 37 42.
-
(2005)
Br J Dermatol
, vol.152
, pp. 37-42
-
-
Johansen, C.1
Kragballe, K.2
Westergaard, M.3
-
17
-
-
0036876857
-
Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis
-
Takahashi H, Ibe M, Nakamura S et al. Extracellular regulated kinase and c-Jun N-terminal kinase are activated in psoriatic involved epidermis. J Dermatol Sci 2002 30 : 94 9.
-
(2002)
J Dermatol Sci
, vol.30
, pp. 94-9
-
-
Takahashi, H.1
Ibe, M.2
Nakamura, S.3
-
18
-
-
36148934536
-
Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin
-
Yu XJ, Li CY, Dai HY et al. Expression and localization of the activated mitogen-activated protein kinase in lesional psoriatic skin. Exp Mol Pathol 2007 83 : 413 418.
-
(2007)
Exp Mol Pathol
, vol.83
, pp. 413-418
-
-
Yu, X.J.1
Li, C.Y.2
Dai, H.Y.3
-
19
-
-
34447534298
-
Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis
-
Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2012 2019.
-
(2007)
J Invest Dermatol
, vol.127
, pp. 2012-2019
-
-
Funding, A.T.1
Johansen, C.2
Kragballe, K.3
-
20
-
-
33746139320
-
Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines
-
Funding AT, Johansen C, Kragballe K et al. Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. J Invest Dermatol 2006 126 : 1784 1791.
-
(2006)
J Invest Dermatol
, vol.126
, pp. 1784-1791
-
-
Funding, A.T.1
Johansen, C.2
Kragballe, K.3
-
21
-
-
31144468296
-
Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2
-
Johansen C, Funding AT, Otkjaer K et al. Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. J Immunol 2006 176 : 1431 1438.
-
(2006)
J Immunol
, vol.176
, pp. 1431-1438
-
-
Johansen, C.1
Funding, A.T.2
Otkjaer, K.3
-
22
-
-
2942530310
-
ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions
-
Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004 68 : 320 344.
-
(2004)
Microbiol Mol Biol Rev
, vol.68
, pp. 320-344
-
-
Roux, P.P.1
Blenis, J.2
-
23
-
-
20544461306
-
Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin
-
Johansen C, Flindt E, Kragballe K et al. Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. J Invest Dermatol 2005 124 : 1284 1292.
-
(2005)
J Invest Dermatol
, vol.124
, pp. 1284-1292
-
-
Johansen, C.1
Flindt, E.2
Kragballe, K.3
-
24
-
-
36249006497
-
The activity of caspase-1 is increased in lesional psoriatic epidermis
-
Johansen C, Moeller K, Kragballe K et al. The activity of caspase-1 is increased in lesional psoriatic epidermis. J Invest Dermatol 2007 127 : 2857 2864.
-
(2007)
J Invest Dermatol
, vol.127
, pp. 2857-2864
-
-
Johansen, C.1
Moeller, K.2
Kragballe, K.3
-
25
-
-
0021982891
-
Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro
-
Kragballe K, Desjarlais L, Marcelo CL. Increased DNA synthesis of uninvolved psoriatic epidermis is maintained in vitro. Br J Dermatol 1985 112 : 263 270.
-
(1985)
Br J Dermatol
, vol.112
, pp. 263-270
-
-
Kragballe, K.1
Desjarlais, L.2
Marcelo, C.L.3
-
26
-
-
0037378429
-
3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes
-
3 stimulates AP-1 DNA binding activity by a PI3-kinase/Ras/MEK/ERK1/2 and JNK1 dependent increase in c-Fos, Fra1 and c-Jun expression in human keratinocytes. J Invest Dermatol 2003 120 : 561 570.
-
(2003)
J Invest Dermatol
, vol.120
, pp. 561-570
-
-
Johansen, C.1
Kragballe, K.2
Henningsen, J.3
-
27
-
-
77952722897
-
-
U.S. Food and Drug Administration. Available at. (last accessed 8 February 2010)
-
U.S. Food and Drug Administration. Adalimumab Product Approval Information. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080610.htm (last accessed 8 February 2010).
-
Adalimumab Product Approval Information
-
-
-
29
-
-
43949126520
-
Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab
-
Mitoma H, Horiuchi T, Tsukamoto H et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008 58 : 1248 1257.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 1248-1257
-
-
Mitoma, H.1
Horiuchi, T.2
Tsukamoto, H.3
-
30
-
-
36749070996
-
Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor alpha agents
-
Nesbitt A, Fossati G, Bergin M et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007 13 : 1323 1332.
-
(2007)
Inflamm Bowel Dis
, vol.13
, pp. 1323-1332
-
-
Nesbitt, A.1
Fossati, G.2
Bergin, M.3
-
31
-
-
23444432216
-
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques
-
Gottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005 175 : 2721 2729.
-
(2005)
J Immunol
, vol.175
, pp. 2721-2729
-
-
Gottlieb, A.B.1
Chamian, F.2
Masud, S.3
-
32
-
-
21344475123
-
Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis
-
Garfield BE, Krahl T, Appel S et al. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis. Clin Immunol 2005 116 : 101 107.
-
(2005)
Clin Immunol
, vol.116
, pp. 101-107
-
-
Garfield, B.E.1
Krahl, T.2
Appel, S.3
-
33
-
-
68949146860
-
Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): P38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis
-
Aerts NE, Ebo DG, Bridts CH et al. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): P38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis. Cytokine 2009 47 : 178 184.
-
(2009)
Cytokine
, vol.47
, pp. 178-184
-
-
Aerts, N.E.1
Ebo, D.G.2
Bridts, C.H.3
-
34
-
-
34547582595
-
No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis
-
Semmler M, Seeck U, Neustadt B et al. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. Clin Rheumatol 2007 26 : 1499 1504.
-
(2007)
Clin Rheumatol
, vol.26
, pp. 1499-1504
-
-
Semmler, M.1
Seeck, U.2
Neustadt, B.3
|